Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Abeona Therapeutics Inc. reported third-quarter ZEVASKYN revenue of $13.5 million, up 18%, a net loss of $(4.8) million and $134.9 million in cash, cash equivalents and short-term investments. It also acquired ABO-801 and announced $30 million in PIPE financing.
- 10-Q report · filed Nov 9, 2026
- Abeona acquired Phase 3-ready ABO-801 for eosinophilic esophagitis from Ellodi for $20 million in stock. Ellodi is eligible for $30 million upon FDA approval and up to an additional $30 million upon sales milestones.
The audio replay and transcript follow the call.